Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
Key Highlights
- ➤ALXN1840 Phase 3 trial met its primary endpoint over 48 weeks
- ➤ALXN1840 showed favorable safety across 645 patient-years in 266 patients
- ➤FoCus Phase 3 baseline Wilson disease data will be presented Nov. 8
- ➤Molybdenum balance and safety data will be presented Nov. 5
Expert Statements
Frederick K. Askari, Associate Professor of Internal Medicine and Director of the Wilson Disease Program, University of Michigan Health System
“Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial”
Aftab Ala, Consultant Hepatologist, Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London
“Neutral Molybdenum Balance and Lack of Molybdenum Toxicity in Subjects Treated with Tiomolibdate Choline Supports Safety Profile of TMC”
WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company’s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting(®) 2026, taking place Nov. 5–9, 2026, at the Colorado Convention Center in Denver, Colorado.
As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-naïve and treatment-experienced patients. These findings will also be available as a companion e-poster via the AASLD website.
Get started
Create a free account to read the full story.